Related Experiment Video
Updated: Jul 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
The JAK kinases: not just another kinase drug discovery target
1SYN|thesis med chem, PO Box 450, South Yarra, Victoria 3141, Australia. andrew.wilks@synmedchem.com
Abstract:
There are four members of the JAK family of protein tyrosine kinases (PTKs) in the human genome. Since their discovery in 1989, great strides have been made in the understanding of their role in normal intracellular signalling. Importantly, their roles in pathologies ranging from cancer to immune deficiencies have placed them front and centre as potential drug targets. The recent discovery of the role of activating mutations in the kinase-like domain (KLD) of JAK2 in the development of polycythemia rubra vera, and the elaboration of KLD mutation as a broader mechanism by which cells might become hyperproliferative has sparked enormous interest in the development of JAK selective drug candidates. I review herein the progress that has been made in the discovery of JAK-targeted inhibitors, and discuss the challenges that face the development of these drugs for use in the clinic.
Insights
Janus kinase (JAK) inhibitors are promising drug candidates for treating cancers and immune disorders. This review covers progress and challenges in developing JAK-targeted therapies, particularly for polycythemia vera.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The Janus kinase (JAK) family comprises four protein tyrosine kinases (PTKs) crucial for intracellular signaling.
- Dysregulation of JAK signaling is implicated in various pathologies, including cancers and immune deficiencies, making them key drug targets.
Purpose of the Study:
- To review the progress in discovering JAK-targeted inhibitors.
- To discuss the challenges associated with developing these inhibitors for clinical applications.
Main Methods:
- Review of scientific literature on JAK inhibitors.
- Analysis of the role of JAK2 kinase-like domain (KLD) mutations in hyperproliferative disorders.
Main Results:
- Activating mutations in JAK2 KLD are linked to polycythemia rubra vera.
- KLD mutations represent a broader mechanism for cellular hyperproliferation, increasing interest in JAK inhibitors.
Conclusions:
- Significant advancements have been made in identifying JAK-targeted inhibitors.
- Further research is needed to overcome challenges in the clinical development of JAK inhibitors for various diseases.
Related Concept Videos
The JAK-STAT Signaling Pathway
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
cAMP-dependent Protein Kinase Pathways
MAPK Signaling Cascades

